ChengDu ShengNuo Biotec (SHA:688117) expects a 101% to 145% rise in its attributable profit to between 114.2 million yuan and 139.6 million yuan in the first three quarters from 56.9 million yuan in the year-ago period, according to a Tuesday filing with the Shanghai bourse.
The peptide drug manufacturer's upbeat forecast is attributable to growing demand for peptide active pharmaceutical ingredients, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments